Tag: KDC-MN-1332

Pinealon (EDR peptide; L-glutamyl-L-aspartyl-L-arginine) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson as part of a multigenerational program to identify tissue-specific short-chain peptides capable of modulating gene expression through direct interaction with chromatin. The compound was identified as one of the shortest biologically active sequences within Cortexin, a complex peptide fraction extracted from bovine cerebral cortex tissue that has been used clinically in several post-Soviet jurisdictions for the treatment of traumatic brain injury, ischemic stroke, and cognitive impairment. Pinealon was subsequently synthesized as a standalone tripeptide and advanced through a series of in vitro and in vivo investigations spanning antioxidant activity, neuroprotection, serotonin biosynthesis regulation, dendritic spine preservation in Alzheimer’s disease models, and preliminary open-label clinical observations in elderly patients with cognitive decline and in patients recovering from craniocerebral trauma.

The proposed mechanism of action is unconventional relative to classical receptor-mediated peptide pharmacology. Due to its low molecular weight (418.41 g/mol) and cationic character, Pinealon is reported to penetrate lipid bilayers and nuclear membranes without requiring surface receptor engagement, gaining direct access to chromatin. Molecular modeling and in vitro binding studies from the Khavinson laboratory have identified complementary binding sites in the promoter regions of several genes relevant to neuroprotection and neurodegeneration, including TPH1 (tryptophan hydroxylase 1, the rate-limiting enzyme in serotonin biosynthesis), SOD2 (mitochondrial superoxide dismutase), GPX1 (glutathione peroxidase 1), PPARA and PPARG (peroxisome proliferator-activated receptor alpha and gamma), CASP3 (caspase-3), and APOE (apolipoprotein E). The proposed binding occurs at specific DNA sequences, principally d(CCTGCC)2 and d(CCAGC)2, through sequence-specific steric and electrostatic complementarity with the major groove of double-stranded DNA. The functional consequence is reported to be destabilization of local DNA secondary structure, alteration of histone modification patterns, and increased accessibility of regulatory regions to transcription factors, resulting in upregulation of neuroprotective gene products and downregulation of pro-apoptotic pathways.

Preclinical pharmacology studies, conducted predominantly by the Khavinson group and affiliated Russian laboratories, have reported that Pinealon produces dose-dependent suppression of reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells; increases cell viability under oxidative stress conditions; delays ERK1/2 activation in neurons exposed to homocysteine; reduces caspase-3 expression and p53 protein synthesis in brain tissue; increases serotonin synthesis in neuronal cultures of rat cerebral cortex; normalizes superoxide dismutase and glutathione peroxidase activity in the brains of hypoxia-sensitive rats; prevents the loss of mushroom-shaped dendritic spines in hippocampal neurons from 5xFAD transgenic mice (a model of familial Alzheimer’s disease); and protects rat offspring from prenatal hyperhomocysteinemia-induced cognitive deficits. In an open-label clinical observation in 72 patients with traumatic brain injury, addition of Pinealon to standard rehabilitation therapy improved memory function in approximately 59 percent of patients.

No completed, peer-reviewed randomized controlled trial of Pinealon has been published in English-language indexed journals as of the date of this monograph. No Phase 1 formal safety study, no Phase 2 efficacy trial, and no Phase 3 registration study exist in any population. The compound has no approved indication in any jurisdiction recognized by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Virtually all published Pinealon research originates from the Khavinson laboratory and closely affiliated institutions; independent replication by Western academic laboratories is absent. The chromatin-interaction model, while supported by computational molecular modeling and fluorescence microscopy studies from the originating group, has not been independently validated by structural biology methods (X-ray crystallography, cryo-electron microscopy) at the resolution required to confirm the proposed binding geometry. This monograph documents the chemistry, proposed mechanism, preclinical pharmacology, clinical observations, sourcing and handling, and comparative assessment of the compound, and identifies the principal evidence gaps that currently limit its positioning in the research-clinical translation pipeline.